Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Omeros Corporation (NASDAQ:OMER) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $40.3333.

Several analysts recently weighed in on OMER shares. HC Wainwright raised their price objective on Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd. Wall Street Zen cut shares of Omeros from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Finally, D. Boral Capital restated a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Tuesday, January 27th.

Insider Buying and Selling

In related news, CAO David J. Borges sold 30,000 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. State of Wyoming bought a new position in shares of Omeros in the 4th quarter valued at $25,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Omeros in the fourth quarter valued at approximately $33,000. Arax Advisory Partners increased its stake in shares of Omeros by 56.4% in the fourth quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 1,894 shares during the period. Farther Finance Advisors LLC raised its holdings in Omeros by 16.5% in the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 1,004 shares during the last quarter. Finally, Osaic Holdings Inc. raised its holdings in Omeros by 34.6% in the 4th quarter. Osaic Holdings Inc. now owns 7,547 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 1,938 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Stock Performance

Shares of OMER opened at $11.27 on Wednesday. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65. The firm has a market cap of $799.04 million, a price-to-earnings ratio of -5.58 and a beta of 2.45. The business’s fifty day moving average is $11.85 and its 200-day moving average is $9.32.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.